about
Prevention and management of tumor lysis syndrome in adults with malignancyConsidering renal risk while managing cancer.Effect of Vitamin D Supplementation on Delayed Hyperphosphatemia in Pediatric Acute Lymphoblastic Leukemia Patients During Induction ChemotherapyElevated baseline potassium level within reference range is associated with worse clinical outcomes in hospitalised patientsTumor Lysis Syndrome in Solid Tumors: An up to Date Review of the LiteratureTumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literatureNephrotoxicity of recent anti-cancer agents.Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceAllopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.Complex coordinated extracellular metabolism: Acid phosphatases activate diluted human leukocyte proteins to generate energy flow as NADPH from purine nucleotide ribose.Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures.Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma.Concurrent acute spontaneous tumor lysis syndrome complicated with multiple organ failure in a patient with pre-existing undiagnosed lung cancer.Spontaneous tumor lysis syndrome in a patient with metastatic prostate cancer.Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?Rasburicase for acute kidney injury.Tumor Lysis Syndrome in Patients with Hematological Malignancies.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.Low-dose rasburicase in hematologic malignancies.Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
P2860
Q27003152-694002E4-CA61-4A6E-8D4B-2BD9CC4DBE46Q30234338-2193F23F-51D1-4EDE-8A71-441CD301EF58Q33620234-B439F225-9552-4E0A-AEDA-383B2C82B5F0Q33729193-BA969D59-B519-4B9E-96E5-03FBF67CE6CBQ33852544-C484892B-4424-4551-8356-8244F411F29FQ35136271-0BB1EBA2-814A-45E9-97D6-4D2DC421CD49Q35310741-6CD07A12-7DDC-44B8-BA33-520156395BB5Q35742173-49B11C6C-CCEF-4F65-AB2B-B753B3C80E62Q35834966-30381736-E0AB-457E-BECE-7275E05FEC86Q36601486-F02E4807-5ADF-4861-BC03-6AB4501EEB4AQ37629478-5EE24C14-A0D2-43BD-BD3F-6D47BDC388F3Q38342838-BA1B8AD1-B968-438A-912D-D610340C8DBCQ38514328-B1D1C757-29AC-435B-A7A5-1C50A6D68C64Q38965174-E87344A9-6C1E-4B60-AA34-715EE3F13A91Q40930613-DC339F5C-A5A3-4901-AEFA-C04E9250CBAFQ42293190-7A7D7B10-DACF-408C-9843-7F300A36DDDDQ42371674-FA31406B-0D17-4324-91C0-89DE1CC9A21FQ44565631-F2D9A7AE-147F-41FA-98F8-326C91FAFD2FQ46949121-8D8CCA1B-AF83-470E-B776-9676937D2A43Q47887134-DA85BBA8-AB8F-4D4C-9C48-511DAA9D040DQ51105458-8441BC25-FDE9-4272-905C-D6375CC4C2FEQ51746631-2F650EBA-B9A3-4DBC-9DD6-D0AA2F7FA849
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Onco-nephrology: tumor lysis syndrome.
@ast
Onco-nephrology: tumor lysis syndrome.
@en
Onco-nephrology: tumor lysis syndrome.
@nl
type
label
Onco-nephrology: tumor lysis syndrome.
@ast
Onco-nephrology: tumor lysis syndrome.
@en
Onco-nephrology: tumor lysis syndrome.
@nl
prefLabel
Onco-nephrology: tumor lysis syndrome.
@ast
Onco-nephrology: tumor lysis syndrome.
@en
Onco-nephrology: tumor lysis syndrome.
@nl
P356
P1476
Onco-nephrology: tumor lysis syndrome
@en
P2093
Jeffrey S Berns
P304
P356
10.2215/CJN.03150312
P577
2012-08-09T00:00:00Z